Followers | 3315 |
Posts | 33124 |
Boards Moderated | 1 |
Alias Born | 06/29/2011 |
Saturday, September 30, 2017 5:19:07 AM
https://fintel.io/i/oakmore-opportunity-fund-i-lp
Oakmore Opportunity Fund I LP trade performance is described in the following table. This page shows potential returns an outside investor could achieve by mimicking trades made by Oakmore Opportunity Fund I LP. To calculate the performance, we look at every reported 13D/G filing made by Oakmore Opportunity Fund I LP in the last three years and measure the profitability of each trade, starting the first trading day after the investment is disclosed.
This is equivalent to the returns that an investor could achieve by following Oakmore Opportunity Fund I LP into investments by purchasing the same securities on the day after a 13D/G is filed. Another way to think of this is that we show the predictive power of an investment by Oakmore Opportunity Fund I LP in the future performance of a security.
Recent HYEX News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:22:30 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 10/24/2023 06:25:27 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 10/06/2023 06:09:39 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/14/2023 05:22:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 06:30:40 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/05/2023 08:24:27 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 08/24/2023 08:12:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:09:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2023 05:30:59 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM